Summarized by Masters of Longevity from FDA - Drugs.
FDA approved dostarlimab-gxly for mismatch repair deficient advanced solid tumors.
Key Takeaways
- The FDA granted accelerated approval to dostarlimab-gxly.
- The VENTANA MMR RxDx Panel was approved as companion diagnostic.
- Approval is limited to mismatch repair deficient tumors.
